Document:

asmb-ex101_29.htm

Exhibit 10.1

 

	
[* * *] Portions of this exhibit that are both not material and would likely cause competitive harm to the registrant if publicly disclosed have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

 

AMENDMENT #1 TO EXCLUSIVE LICENSE AGREEMENT

 

This Amendment #1 to Exclusive License Agreement (“Amendment #1”) is entered into as of February 28, 2017 (the “Amendment #1 Effective Date”) by and between The Indiana University Research and Technology Corporation, a non-profit corporation organized under the laws of the state of Indiana, having its principal offices at 518 Indiana Ave, Indianapolis, IN 46202 (“IURTC”) and Assembly Biosciences, Inc. (the parent company and assignee of Assembly Pharmaceuticals, Inc.), a company organized under the laws of the state of Delaware, having its principal offices at 11711 N. Meridian Street, Suite 310, Carmel, Indiana, 46032 (“Assembly”) and acknowledged by Assembly Pharmaceuticals, Inc., a Delaware corporation and wholly owned subsidiary of Assembly (“AP”). IURTC and Assembly may each be referred to herein as a “Party” and collectively as the “Parties”.

 

WHEREAS, IURTC and Assembly, as assignee of AP, are parties to that ce1tain Exclusive License Agreement dated as of September 3, 2013 (the “License Agreement”).

 

WHEREAS, the Parties desire to amend the License Agreement to include within the scope of the exclusive license certain additional patent applications, including patent applications that are co- owned by Assembly.

 

NOW THEREFORE, in consideration of the mutual covenants and promises contained herein and in the License Agreement, IURTC and Assembly agree as follows:

 

	
1.
	
Section 3.5 of the License Agreement is hereby deleted and replaced in its entirety with the following:

 

	
 
	
“3.5 
	
This Agreement provides Assembly and Sublicensees no ownership rights of any kind in the Patent Rights, provided that the Parties acknowledge that Assembly has joint ownership rights in certain Patent Rights as set forth on Exhibit A. All ownership rights, other than such joint ownership rights owned by Assembly, remain the property of the Institutions and/or IURTC.”

 

	
2.
	
The following is hereby added as Section 9.8 of the License Agreement:

 

	
 
	
“9.8
	
Notwithstanding anything in this Agreement to the contrary, the Parties acknowledge and agree that for the patent applications listed on Exhibit A that are identified as “Protein Modulator Patents” (including all associated Patent Rights) (such patent applications and associated Patent Rights, collectively, the “Protein Modulator Patent Rights”) that Assembly is a co-owner of the Protein Modulator Patent Rights and, notwithstanding anything in Sections 9.1 through 9.7 to the contrary , the Parties agree that: 

 

	
 
	
9.8.1
	
Assembly will have exclusive control of the preparation, filing, prosecution, issue and maintenance of the Protein Modulator Patent Rights. Assembly will select qualified patent counsel reasonably acceptable to IURTC to prepare, file, prosecute and maintain the Protein Modulator Patent Rights. Assembly will keep IURTC fully informed of patent prosecution, will seek IURTC's comments and suggestions prior to taking material actions for the same, and will take all prosecution actions reasonably recommended by IURTC which would expand the scope of rights sought.

 

 

	
 
	
9.8.2
	
Assembly will authorize IURTC to communicate directly with Assembly’s patent counsel. All information exchanged among Assembly's counsel, the Parties, and/or the inventors regarding the preparation, filing, prosecution, issue, or maintenance of the Protein Modulator Patent Rights will be deemed Confidential Information. In addition, the Parties acknowledge and agree that with regard to such preparation, filing, prosecution, issue, and maintenance of the Protein Modulator Patent Rights, the interests of the Parties as licensee and licensor are to obtain the strongest and broadest patent protection possible, and as such are aligned and legal in nature. The Parties agree and acknowledge that they have not waived, and nothing in this Agreement constitutes a waiver of, any legal privilege concerning the Protein Modulator Patent Rights, including without limitation, privilege under the common interest doctrine and similar or related doctrines.

 

	
 
	
9.8.3
	
Assembly will not abandon the prosecution of any patent application or the maintenance of any patent under the Protein Modulator Patent Rights without prior written notice to IURTC. Upon receiving such written notice, IURTC, at its sole option, may take over the prosecution of any such patent application or the maintenance of any such issued patent in accordance with Sections 9.1 through 9.7.”

 

	
3.
	
Exhibit A of the License Agreement is hereby deleted in its entirety and is replaced with the Exhibit A attached hereto.

 

	
4.
	
Except as specifically modified by this Amendment #1, the Parties agree that all of the terms and conditions set forth in the License Agreement remain in full force and effect.

 

	
5.
	
The Parties and AP acknowledge and agree that AP has assigned the License Agreement to Assembly and Assembly has assumed all the obligations and liabilities of AP under the License Agreement following that certain merger by and among Assembly, AP and a wholly owned subsidiary of Assembly effected on July 11, 2014.

 

[Signature Page Follows]

 

 

 

IN WITNESS WHEREOF, the Parties have caused this Amendment #1 to be executed by their duly authorized representatives as of the Amendment #1 Effective Date.

 

	
ASSEMBLY BIOSCIENCES, INC.
	
 
	
THE INDIANA UNIVERSITY RESEARCH

	
 
	
 
	
 
	
 
	
AND TECHNOLOGY CORPORATION

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
By:
	
 
	
/s/ Derek A. Small
	
 
	
By:
	
 
	
/s/ Marie Kerbeshian

	
Name:
	
 
	
Derek A Small
	
 
	
Name:
	
 
	
Marie Kerbeshian

	
Title:
	
 
	
CEO
	
 
	
Title:
	
 
	
Vice President Office of Technology

	
 
	
 
	
 
	
 
	
 
	
 
	
Commercialization

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
Solely for Purposes of Acknowledging the assignment 

	
of the License Agreement:

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
ASSEMBLY PHARMACEUTICALS, INC.
	
 
	
 
	
 
	
 

	
 
	
 
	
 
	
 
	
 
	
 
	
 

	
By:
	
 
	
/s/ Derek A. Small
	
 
	
 
	
 
	
 

	
Name:
	
 
	
Derek A Small
	
 
	
 
	
 
	
 

	
Title:
	
 
	
CEO
	
 
	
 
	
 
	
 

 

 

 

[Signature Page to Amendment No. 1 to Exclusive License Agreement]

 

Exhibit A

Patent Rights

 

[* * *]

 

[Signature Page to Amendment No. 1 to Exclusive License Agreement]asmb-ex102_30.htm

Exhibit 10.2

 

	
	
[* * *] Portions of this exhibit that are both not material and would likely cause competitive harm to the registrant if publicly disclosed have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

 

IURTC Agreement No. 2020-0121

 

AMENDMENT #2 TO EXCLUSIVE LICENSE AGREEMENT

This Amendment #2 to Exclusive License Agreement (this “Amendment #2”) is entered into and effective as of July 10, 2020 (the “Amendment #2 Effective Date”) by and between Indiana University Research and Technology Corporation, a non-profit corporation organized under the laws of the state of Indiana, having its principal offices at 518 Indiana Ave., Indianapolis, Indiana 46202 (“IURTC”) and Assembly Biosciences, Inc. (the parent company and assignee of Assembly Pharmaceuticals, Inc.), a Delaware corporation, having its principal offices at 331 Oyster Point Blvd., Fourth Floor, South San Francisco, California 94080 (“Assembly”). IURTC and Assembly may each be referred to herein as a “Party” and collectively as the “Parties”. 

WHEREAS, IURTC and Assembly, as assignee of Assembly Pharmaceuticals, Inc., a Delaware corporation and wholly owned subsidiary of Assembly, are parties to that certain Exclusive License Agreement dated as of September 3, 2013 with IURTC Agreement No. 2014-0134 (formerly ASS-0313-BB) as amended by Amendment #1 to Exclsuive License Agreement dated as of February 28, 2017 with IURTC Agreement No. 2017-0180 (collectively, the “License Agreement”).

WHEREAS, the Parties desire to amend the License Agreement to clarify the rights of Sublicensees under the License Agreement and clarify the scope of the Patent Rights subject to the License Agreement; and

NOW THEREFORE, in consideration of the mutual covenants and promises contained herein and in the License Agreement, IURTC and Assembly agree as follows: 

1.Amendments to the License Agreement.  As of the Amendment #2 Effective Date, the License Agreement is hereby amended or modified as follows:

1.1The first paragraph of Section 3.3 of the License Agreement is hereby deleted and replaced in its entirety as follows:

“Assembly may grant Sublicenses to non-Affiliate third parties under this Agreement. Only Assembly, and not its Affiliates, is permitted to grant Sublicenses. Notwithstanding the foregoing, Sublicensees may grant sub-sublicenses (through multiple tiers) under the Agreement solely: (i) to their Affiliates, provided that any such sub-sublicenses shall automatically terminate if the sub-sublicensee party thereto ceases to be an Affiliate of the Sublicensee; (ii) subject to the terms of the Sublicense, to contract research organizations, distributors and other third party subcontractors for the sole purpose of performing Sublicensee’s obligations under the Sublicense; and (iii) to any other third party subject to IURTC’s prior written consent, not to be unreasonably withheld, conditioned or delayed.”

1.2Section 3.3.4 of the License Agreement is hereby deleted and replaced in its entirety as follows:

“Assembly agrees to be fully responsible for the performance of its Sublicensees hereunder and any sub-sublicensees under any sub-sublicenses granted by Sublicensee. Any act or omission by a Sublicensee or sub-sublicensee that would be a breach of this Agreement if imputed to Assembly will be deemed to be a breach by Assembly of this Agreement.”

1.3Section 6.1.1 of the License Agreement is deleted and replaced in its entirety as follows:

“Checks will be sent to:
Indiana University Research and Technology Corporation
Attn: Innovation and Commercialization Office
518 Indiana Avenue
Indianapolis, IN 46202

The IURTC Agreement No. 2014-0134 (formerly ASP- 0313 BB) and purpose of the payment will be included with the check.”

 

IURTC Agreement No. 2020-0121

 

1.4Section 15 of the License Agreement is hereby modified to replace IURTC’s notice address as follows:

“Notice:  Any required or permissive notice under this Agreement will be sufficient if in writing and delivered personally, by recognized national overnight courier, or by registered or certified mail, postage prepaid and return receipt requested, to the address below and will be deemed to have been given as of the date shown on the receipt if by certified or registered mail, or the day following dispatch if by overnight courier.

If to IURTC:
The Trustees of Indiana University
Attn: Innovation and Commercialization Office
IURTC Agreement No. 2014-0134 (formerly ASP-0313-BB)
107 S. Indiana Ave., Bryan Hall 211
Bloomington, IN 47405

With copy to:
Indiana University Research and Technology Corporation
Attn: Innovation and Commercialization Office
IURTC Agreement No. 2014-0134 (formerly ASP-0313-BB) 
518 Indiana Avenue
Indianapolis, IN 46202

If to Assembly:
Assembly Biosciences, Inc.
Attn: Chief Legal and Business Officer
331 Oyster Point Blvd., Fourth Floor
South San Francisco, CA 94080”

1.5Exhibit A of the License Agreement is hereby deleted and replaced in its entirety with the Exhibit A attached hereto.

2.Limited Effect. Except as specifically modified by this Amendment #2, the Parties agree that all of the terms and conditions set forth in the License Agreement remain in full force and effect.

3.Counterparts; Signatures. This Amendment #2 may be executed in any number of counterparts, each of which taken together shall be deemed to constitute one and the same agreement. The Parties agree that execution of this Amendment #2 by industry standard electronic signature software and/or by exchanging executed signature pages in .pdf format via e-mail shall have the same legal force and effect as the exchange of original signatures, and that in any proceeding arising under or related to this Amendment #2, each party hereby waives any right to raise any defense or waiver based upon execution of this Amendment #2 by means of such electronic signatures or maintenance of the executed agreement electronically.

IN WITNESS WHEREOF, the parties have caused this Amendment #2 to be executed and delivered by their duly authorized representatives as of the Amendment #2 Effective Date. 

 

							
	
ASSEMBLY BIOSCIENCES, INC.
	
 
	
INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

	
By:
	
 
	
/s/ Jason A. Okazaki
	
 
	
By:
	
 
	
/s/ Simran Trana

	
Name:
	
 
	
Jason A. Okazaki
	
 
	
Name:
	
 
	
Simran Trana

	
Title:
	
 
	
Chief Legal and Business Officer
	
 
	
Title:
	
 
	
Associate VP, ICO

 

 

IURTC Agreement No. 2020-0121

 

Exhibit A

Patent Rights

 

[* * *]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00316-of-00352.parquet"}]]